To describe trends in Medicare Part D drug spending for disease-modifying therapies (DMTs) in multiple sclerosis (MS) as well as autoimmune neurological-related disorders (ANRD) from 2013 to 2021.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: